Table 1.
Detailed characteristics of the pSS group.
| Parameter (Mean ± SD or n (%)) |
pSS Group n = 46 |
|---|---|
| disease duration (years) | 5.47 ± 0.68 |
| RF positivity | 34 (73.9) |
| ANA > 1:320 | 46 (100) |
| anti-Ro/SS-A antibodies positivity ^ | 37 (84) |
| anti-La/SS-B antibodies positivity ^ | 30 (68.1) |
| positive labial salivary gland biopsy | 42 (91.3) |
| hypergammaglobulinemia | 16 (34.7) |
| low complement # | 6 (13) |
| leukopenia | 15 (32.6) |
| ESSDAI | 9.50 ± 0.86 |
| ESSPRI | 4.37 ± 0.29 |
| Anti-malarial drugs use | 24 (52.17) |
| DMARDs use | 35 (76) |
| xerostomia | 39 (84.7) |
| xerophthalmia | 39 (84.7) |
| arthritis/arthralgia * | 43 (93.4) |
| pulmonary involvement * (ILD confirmed by HRCT) | 10 (21.7) |
| parotid enlargement * | 8 (17.3) |
| Raynaud’s phenomenon | 5 (10.8) |
| Lymphadenopathy * | 11 (23.9) |
| renal involvement * | 3 (6.5) |
| peripheral nervous system involvement * | 3 (6.5) |
| cutaneus involvement * | 6 (13) |
Abbreviations: ANA—anti-nuclear antibody, DMARDs- disease-modifying antirheumatic drugs, ESSDAI—EULAR Sjogren’s Syndrome Disease Activity Index, ESSPRI—EULAR Sjogren’s Syndrome Patient Reported Index, HRCT—high-resolution computed tomography, ILD—interstitial lung disease, RF—rheumatoid factor. * defined by ESSDAI domains, # reduced C3 and/or C4 levels, ^ evaluated using commercial ELISA kits.